217 related articles for article (PubMed ID: 35717937)
1. Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity.
García-Carro C; Draibe J; Soler MJ
Nephron; 2023; 147(2):65-77. PubMed ID: 35717937
[TBL] [Abstract][Full Text] [Related]
2. Onconephrology: The intersections between the kidney and cancer.
Rosner MH; Jhaveri KD; McMahon BA; Perazella MA
CA Cancer J Clin; 2021 Jan; 71(1):47-77. PubMed ID: 32853404
[TBL] [Abstract][Full Text] [Related]
3. Onconephrology: the latest frontier in the war against kidney disease.
Salahudeen AK; Bonventre JV
J Am Soc Nephrol; 2013 Jan; 24(1):26-30. PubMed ID: 23138480
[TBL] [Abstract][Full Text] [Related]
4. Onconephrology: mitigation of renal injury in chemotherapy administration.
Selamet U; Ahdoot RS; Salasnek R; Abdelnour L; Hanna RM
Curr Opin Nephrol Hypertens; 2024 Mar; 33(2):257-266. PubMed ID: 38095483
[TBL] [Abstract][Full Text] [Related]
5. [Ten Years of Onconephrology].
Cosmai L
G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007821
[TBL] [Abstract][Full Text] [Related]
6. Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists.
Matsubara T; Yokoi H; Yamada H; Yanagita M
Int J Clin Oncol; 2023 May; 28(5):625-636. PubMed ID: 36872414
[TBL] [Abstract][Full Text] [Related]
7. Nephrotoxicity in cancer treatment: An update.
Chen C; Xie D; Gewirtz DA; Li N
Adv Cancer Res; 2022; 155():77-129. PubMed ID: 35779877
[TBL] [Abstract][Full Text] [Related]
8. [Renal Side Effects of Novel Molecular Targeted Oncologic Agents].
Fenoglio R; Cortazzi S; Marchisio M; Rabajoli G; Terzolo E; Sciascia S; Roccatello D
G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007829
[TBL] [Abstract][Full Text] [Related]
9. Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations.
Piscitani L; Sirolli V; Di Liberato L; Morroni M; Bonomini M
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664269
[TBL] [Abstract][Full Text] [Related]
10. [Nephrotoxicity induced by chemotherapy].
Di Vito R; Sirolli V; Amoroso L; Bonomini M
G Ital Nefrol; 2011; 28(3):296-304. PubMed ID: 21626498
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy.
Parodi E; Rossi M; Bottiglieri A; Ladetto M; Merlotti G; Cantaluppi V; Quaglia M
Expert Opin Pharmacother; 2024 Apr; 25(5):595-610. PubMed ID: 38646905
[TBL] [Abstract][Full Text] [Related]
12. Perspectives From an Onconephrology Interest Group: Conference Report.
Kitchlu A; Chan CT; Leung N; Chen S; Latcha S; Tam P
Can J Kidney Health Dis; 2020; 7():2054358120962589. PubMed ID: 33117547
[TBL] [Abstract][Full Text] [Related]
13. Update on the nephrotoxicity of novel anticancer agents
.
Nussbaum EZ; Perazella MA
Clin Nephrol; 2018 Mar; 89(3):149-165. PubMed ID: 29350175
[TBL] [Abstract][Full Text] [Related]
14. Onconephrology: A New Challenge for the Nephrologist.
Fofi C; Festuccia F
Contrib Nephrol; 2021; 199():91-105. PubMed ID: 34375977
[TBL] [Abstract][Full Text] [Related]
15. Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer.
Jagieła J; Bartnicki P; Rysz J
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924827
[TBL] [Abstract][Full Text] [Related]
16. Lung cancer-kidney cross talk induces kidney injury, interstitial fibrosis, and enhances cisplatin-induced nephrotoxicity.
Orwick A; Sears SM; Sharp CN; Doll MA; Shah PP; Beverly LJ; Siskind LJ
Am J Physiol Renal Physiol; 2023 Mar; 324(3):F287-F300. PubMed ID: 36727944
[TBL] [Abstract][Full Text] [Related]
17. Onconephrology: Core Curriculum 2023.
Yarandi N; Shirali AC
Am J Kidney Dis; 2023 Dec; 82(6):743-761. PubMed ID: 37855786
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy-Related Acute Kidney Injury.
Manohar S; Jhaveri KD; Perazella MA
Adv Chronic Kidney Dis; 2021 Sep; 28(5):429-437.e1. PubMed ID: 35190109
[TBL] [Abstract][Full Text] [Related]
19. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
20. [Cancer Treatment-induced Changes in Renal Function in Patients with Tumors - Update on Current Knowledge].
Pokrivčák T; Poprach A
Klin Onkol; 2017; 31(1):28-34. PubMed ID: 29488775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
